---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072016"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:42:49.741987+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated

## Summary
- Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.
- Cash, equivalents and restricted cash ~$100M; cash runway expected into H2 2026, funding PBGENE-HBV and PBGENE-DMD through Phase 1 data.
- PBGENE-HBV cleared for U.S. Phase 1 (FDA IND) and UK (MHRA); Fast Track designation granted; initial safety data presented at EASL.
- PBGENE-DMD prioritized as second wholly owned program; IND/CTA target in 2025 with clinical data expected in 2026.
- PBGENE-3243 development paused to focus resources on HBV and DMD programs.

## SEC filing metadata
- accession: 0000950170-25-072016
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/0000950170-25-072016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/dtil-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072016
- JSON: https://secwatch.observer/filing/0000950170-25-072016.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.